{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:16:18Z","timestamp":1781525778354,"version":"3.54.1"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Although there are different tools to evaluate axial spondyloarthritis (axSpA), they are hardly used in routine clinical practice due to time constraints. The Routine Assessment of Patient Index Data 3 (RAPID3) is a composite measure feasible for use as a sole metric in busy clinics. We aimed to test its measurement properties in patients with axial SpA in a real-world clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cross-sectional study included 131 consecutive patients with axial SpA. The convergent (Spearman \u03c1) and discriminant (receiver-operating characteristic [ROC] curve analysis) validity of RAPID3 were tested against several axSpA-specific measures (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Ankylosing Spondylitis Disease Activity Score [ASDAS], Bath Ankylosing Spondylitis Functional Index [BASFI], and modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS]). A multivariate model was built to detect disease factors associated with RAPID3 remission (values \u2264 3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 82 men and 49 women, with a median age of 55 (IQR 46\u201361) years, and a median disease duration of 11 (IQR 6\u201324) years. Mean RAPID3 was 9.45 \u00b1 6.7. The BASDAI showed moderate correlation with ASDAS (\u03c1 0.66,<jats:italic>P<\/jats:italic>&lt; 0.0001), but higher correlations with BASFI (\u03c1 0.78,<jats:italic>P<\/jats:italic>&lt; 0.0001) and RAPID3 (\u03c1 0.75,<jats:italic>P<\/jats:italic>&lt; 0.0001). The ASDAS had moderate correlations with BASFI, BASDAI, and RAPID3 (ranges 0.66\u20130.68,<jats:italic>P<\/jats:italic>&lt; 0.0001). Higher correlations were found between BASFI and BASDAI (\u03c1 0.78,<jats:italic>P<\/jats:italic>&lt; 0.0001), and BASFI and RAPID3 (\u03c1 0.73,<jats:italic>P<\/jats:italic>&lt; 0.0001). The mSASSS did not show any correlation with any of the above composite measures. \u03ba agreement between RAPID3 remission and other SpA remission criteria was moderate (\u03ba 0.46\u20130.56). The RAPID3 thresholds to define remission ranged from values \u2264 2 to \u2264 6 with areas under the ROC curve between 0.86\u20130.91. Female sex (OR 0.34, 95% CI 0.12\u20130.90,<jats:italic>P<\/jats:italic>= 0.03) and nonsteroidal antiinflammatory drug intake (OR 0.26, 95% CI 0.10\u20130.66,<jats:italic>P<\/jats:italic>= 0.005) were independently associated with lower odds of achieving RAPID3 remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RAPID3 demonstrated construct validity in this cross-sectional study. This index can be useful for a more comprehensive assessment of axSpA in busy clinical settings.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.201362","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:20:50Z","timestamp":1626351650000},"page":"36-43","source":"Crossref","is-referenced-by-count":16,"title":["Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis"],"prefix":"10.3899","volume":"49","author":[{"given":"Andrea","family":"Garc\u00eda-Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Andr\u00e9s-de Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aar\u00f3n Josu\u00e9","family":"Fari\u00f1a-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Daniel","family":"Gonz\u00e1lez-Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"2024092708501829000_49.1.36.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2024092708501829000_49.1.36.2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2024092708501829000_49.1.36.3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2024092708501829000_49.1.36.4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/BOR.0000000000000588","article-title":"Measuring outcomes in ankylosing spondylitis: pearls and pitfalls","volume":"31","author":"Magrey","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2024092708501829000_49.1.36.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203967"},{"key":"2024092708501829000_49.1.36.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200025"},{"key":"2024092708501829000_49.1.36.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.017"},{"key":"2024092708501829000_49.1.36.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582"},{"key":"2024092708501829000_49.1.36.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3256-7"},{"key":"2024092708501829000_49.1.36.10","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000277"},{"key":"2024092708501829000_49.1.36.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2827-4"},{"key":"2024092708501829000_49.1.36.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000235"},{"key":"2024092708501829000_49.1.36.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2024092708501829000_49.1.36.14","first-page":"993","article-title":"Stoke Ankylosing Spondylitis Spine Score","volume":"26","author":"Dawes","year":"1999","journal-title":"J Rheumatol"},{"key":"2024092708501829000_49.1.36.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2024092708501829000_49.1.36.16","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2024092708501829000_49.1.36.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2024092708501829000_49.1.36.18","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2024092708501829000_49.1.36.19","first-page":"S705","article-title":"An index based on only patient reported outcome (PRO) measures, without formal joint counts, Routine Assessment of Patient Index Data (RAPID) classifies patients into 4 severity categories which are similar to Disease Activity Score (DAS28) and Clinical Disease Activity Index (CDAI) categories in 4 adalimumab clinical trials [abstract]","volume":"56","author":"Pincus","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024092708501829000_49.1.36.20","doi-asserted-by":"crossref","first-page":"105116","DOI":"10.1016\/j.jbspin.2020.105116","article-title":"Structural damage is not a major driver of disease impact in patients with long-standing psoriatic arthritis undergoing systemic therapy","volume":"88","author":"Queiro","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2024092708501829000_49.1.36.21","doi-asserted-by":"crossref","first-page":"e0196281","DOI":"10.1371\/journal.pone.0196281","article-title":"Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-\u03b1 inhibitors","volume":"13","author":"Carbo","year":"2018","journal-title":"PLoS One"},{"key":"2024092708501829000_49.1.36.22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13075-018-1626-8","article-title":"Widespread pain in axial spondyloarthritis: clinical importance and gender differences","volume":"20","author":"Swinnen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024092708501829000_49.1.36.23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/acr.23924","article-title":"Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis","volume":"72","author":"Smith","year":"2020","journal-title":"Arthritis Care Res"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:51:19Z","timestamp":1727452279000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.3899\/jrheum.201362"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201362","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}